LienTeh.net > Pembrolizumab

Pembrolizumab

KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment is approved in European for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)

2021-10-27 590 Times Pembrolizumab

KENILWORTH, N.J.--October 22, 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors…
Keytruda（Pembrolizumab）combination is approved in the US for the first-line treatment of cervical cancer

2021-10-14 612 Times Pembrolizumab

KENILWORTH, N.J. October 13, 2021 Eastern Daylight Time The FDA approved combining Merck & Co.'s anti-PD-1 therapy Keytruda (pembrolizumab) plus chemotherapy, with or without Roche's Avastin (bevacizumab), for patients with persistent, recurrent or metastatic cervical cancer whose tumours express PD-L1 with a combined positive score (CPS) ≥1. The approval is…

KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment is approved in European for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)